oral GLP-1

Advertisement

cGxPJobs Banner

FDA Clears Ascletis ASC30 Phase II Diabetes Study

HONG KONG, Jan. 5, 2026 — Ascletis Pharma Inc. announced that it has received Investigational New Drug (IND) clearance...

By cGxPwire Editor
January 5, 2026

Read More

Lilly’s Oral GLP-1 Orforglipron Sustains Weight Loss in Phase 3 Trial

Indianapolis, December 18, 2025 — Eli Lilly and Company announced positive topline results from its first-of-its-kind Phase 3 ATTAIN-MAINTAIN...

By cGxPwire Editor
December 19, 2025

Read More

Bio-Pharma Pharma

Lilly’s Oral GLP-1 Orforglipron Delivers Strong Phase 3 Results in Type 2 Diabetes

INDIANAPOLIS, Oct. 15, 2025 — Eli Lilly and Company (NYSE: LLY) announced positive topline results from two pivotal Phase...

By cGxPwire Editor
October 15, 2025

Read More

Advertisement

cGxPJobs

Directory